Epistem Holdings plc Appoints David Budd as Chief Executive Officer and Board of Director, Effective March 1, 2016

EpiStem Holdings Plc announced the appointment of David Budd as Chief Executive Officer and Board of Director. David Budd will join the company on March 1, 2016. David has over 20 years of international commercial and operational experience in the diagnostics and medical devices field.

He joins from Leica Biosystems, where he served as General Manager of Leica Biosystems Amsterdam. David previously served as Commercial Director at Leica Biosystems Newcastle. Prior to joining Leica Biosystems, David's previous roles included Point-of-Care, molecular, and central laboratory marketing and commercialization responsibilities as a Director of Marketing at Siemens Healthcare Diagnostics, Business Unit Leader at Bayer Diagnostics UK, and Sales Manager at Visible Genetics Inc.